.jpg)
Dosage regimen patent claims in Europe
01 October 2009
Maximum patent term protection is key to maintaining market exclusivity for important commercial products. Typical vehicles for achieving this are second (and subsequent) medical use patent claims, supplementary protection certificates (SPCs), orphan drug provisions, and data & marketing exclusivity provisions.
Reduced translation costs for European patents
01 February 2008
The London Agreement will finally enter into force on 1 May 2008 significantly reducing the translation costs for the validation of European patents. European patents granted on or after 1 May 2008 will benefit from significantly reduced translation costs when validated in countries which are party to the Agreement.
London agreement article
01 November 2007
The translation costs incurred when validating a European patent should fall dramatically from early 2008, when the London Agreement is expected to come into force.
